Integrated personalized cell technologies for improving health outcomes in children and adults

UW Carbone Cancer Center Receives FDA Clearance to Test New Regenerative Medicine Therapy for Radiotherapy-Induced Dry Mouth

The University of Wisconsin Carbone Cancer Center has the go-ahead to start clinical trials on a first-in-human cell therapy to treat a common side effect of radiation therapy.

This investigational new drug license, or IND, recently issued by the Food and Drug Administration will allow UW oncologists to study a new cell therapy to treat radiotherapy-induced xerostomia, also called dry mouth.

The new IND offers an entirely novel use of personalized cell therapy with the patient’s own interferon-gamma activated marrow stromal cells, according to Jacques Galipeau, MD, associate dean for therapeutics development and director of the UW Program for Advanced Cell Therapy.

Read the full article at: